

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect, or any other forms of damages arising from this translation.



February 14, 2025

## Consolidated Financial Results for the Six Months Ended December 31, 2024 (Under Japanese GAAP)

Company name: ASAHI INTECC CO., LTD.  
 Listing: Tokyo Stock Exchange and Nagoya Stock Exchange  
 Securities code: 7747  
 URL: <https://www.asahi-intecc.co.jp/>  
 Representative: Kenji Miyata, President & CEO  
 Inquiries: Mizuho Ito, Director, General Manager of Administration Division  
 Telephone: +81-561-48-5551  
 Scheduled date of filing semi-annual report: February 14, 2025  
 Scheduled date of commencing dividend payments: —  
 Preparation of supplementary material on financial results: Yes  
 Holding of financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

### 1. Consolidated financial results for the six months ended December 31, 2024 (from July 1, 2024 to December 31, 2024)

#### (1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

|                   | Net sales   |      | Operating profit<br>excluding goodwill<br>amortization, etc. |      | Operating profit |      | Ordinary profit |      | Profit attributable to<br>owners of parent |      |
|-------------------|-------------|------|--|------|------------------|------|-----------------|------|--|------|
| Six months ended  | Million yen | %    | Million yen  | %    | Million yen      | %    | Million yen     | %    | Million yen                                | %    |
| December 31, 2024 | 61,491      | 13.2 | 18,402   | 27.1 | 17,395           | 28.9 | 16,821          | 24.9 | 12,261                                     | 24.9 |
| December 31, 2023 | 54,341      | 19.6 | 14,484   | 32.9 | 13,498           | 35.6 | 13,471          | 40.0 | 9,820                                      | 31.4 |

Note: Comprehensive income For the six months ended December 31, 2024: ¥12,501 million (28.9%)  
 For the six months ended December 31, 2023: ¥9,700 million (36.3%)

|                   | Basic earnings<br>per share | Diluted earnings<br>per share |
|-------------------|-----------------------------|-------------------------------|
| Six months ended  | Yen                         | Yen                           |
| December 31, 2024 | 45.14                       | —                             |
| December 31, 2023 | 36.15                       | —                             |

#### (2) Consolidated financial position

|                   | Total assets | Net assets  | Equity-to-asset ratio |
|-------------------|--------------|-------------|-----------------------|
| As of             | Million yen  | Million yen | %                     |
| December 31, 2024 | 190,130      | 158,923     | 83.2                  |
| June 30, 2024     | 191,614      | 151,961     | 78.9                  |

Reference: Equity

As of December 31, 2024: ¥158,153 million  
 As of June 30, 2024: ¥151,217 million

## 2. Dividends

|   | Annual dividends per share |                    |                   |                 |              |
|---|----------------------------|--------------------|-------------------|-----------------|--------------|
|   | First quarter-end          | Second quarter-end | Third quarter-end | Fiscal year-end | Total        |
| Fiscal year ended June 30, 2024             | Yen<br>—                   | Yen<br>0.00        | Yen<br>—          | Yen<br>20.37    | Yen<br>20.37 |
| Fiscal year ending June 30, 2025            | —                          | 0.00               |                   |                 |              |
| Fiscal year ending June 30, 2025 (Forecast) |                            |                    | —                 | 24.23           | 24.23        |

Note: Revisions to dividend forecasts announced most recently: None

## 3. Consolidated financial results forecast for the fiscal year ending June 30, 2025 (July 1, 2024 to June 30, 2025)

(Percentages indicate year-on-year changes.)

|           | Net sales   |     | Operating profit excluding goodwill amortization, etc. |      | Operating profit |      | Ordinary profit |      | Profit attributable to owners of parent |      | Basic earnings per share |
|-----------|-------------|-----|--|------|------------------|------|-----------------|------|---|------|--------------------------|
|           | Million yen | %   | Million yen  | %    | Million yen      | %    | Million yen     | %    | Million yen                             | %    | Yen                      |
| Full year | 116,737     | 8.5 | 27,170   | 12.4 | 25,210           | 13.9 | 25,528          | 16.2 | 18,803                                  | 18.9 | 69.22                    |

(Notes) 1. Revisions to financial results forecast announced most recently: None

2. Operating profit excluding goodwill amortization, etc. = Operating profit + amount of goodwill amortization, etc.

**\* Notes**

(1) Significant changes in scope of consolidation during the period: None

Newly included: -

Excluded: -

(2) Accounting treatments adopted specially for the preparation of semi-annual consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(4) Number of issued shares (common stock)

(i) Total number of issued shares at the end of the period (including treasury shares)

|                         |                    |
|-------------------------|--------------------|
| As of December 31, 2024 | 271,633,600 shares |
| As of June 30, 2024     | 271,633,600 shares |

(ii) Number of treasury shares at the end of the period

|                         |              |
|-------------------------|--------------|
| As of December 31, 2024 | 7,977 shares |
| As of June 30, 2024     | 7,955 shares |

(iii) Average number of shares during the period (cumulative)

|                                    |                    |
|------------------------------------|--------------------|
| Six months ended December 31, 2024 | 271,625,630 shares |
| Six months ended December 31, 2023 | 271,625,670 shares |

\* Semi-annual financial results reports are exempt from review by certified public accountants or an audit firm.

\* Proper use of earnings forecasts, and other special matters

Financial results forecasts and other forward-looking statements provided in these materials are based on information available to the Company and certain other assumptions deemed reasonable as of the date of publication of this document, and do not represent any guarantee that the Company will achieve these results. Actual financial results and other aspects of business performance may differ significantly from these forecasts owing to various factors. Please refer to “1. Qualitative information on semi-annual financial results (3) Explanation of forecasts including consolidated results forecast” on page 3 of the attached materials for conditions forming the basis for financial results forecasts, notes regarding the use of financial results forecasts, and other information.

## Table of contents of the attached materials

|  |    |
|--|----|
| 1. Qualitative information on semi-annual financial results .....                  | 2  |
| (1) Explanation of operating results .....   | 2  |
| (2) Explanation of financial position .....  | 3  |
| (3) Explanation of forecasts including consolidated results forecast .....         | 3  |
| 2. Semi-annual consolidated financial statements and major notes .....             | 4  |
| (1) Semi-annual consolidated balance sheet .....                                   | 4  |
| (2) Semi-annual consolidated statements of income and comprehensive income .....   | 6  |
| Semi-annual consolidated statement of income .....                                 | 6  |
| Semi-annual consolidated statement of comprehensive income .....                   | 7  |
| (3) Semi-annual consolidated statement of cash flows .....                         | 8  |
| (4) Notes to semi-annual consolidated financial statements .....                   | 10 |
| (Note on entity's ability to continue as going concern) .....                      | 10 |
| (Notes in the case of significant changes in amount of shareholders' equity) ..... | 10 |
| (Changes in accounting policies) .....   | 10 |
| (Segment Information, etc.) .....  | 11 |
| (Revenue recognition) .....  | 12 |
| (Significant subsequent events) .....  | 13 |

## 1. Qualitative information on semi-annual financial results

### (1) Explanation of operating results

The Asahi Intecc Group (the Group) has formulated the following four basic policies in the medium-term management plan “ASAHI Going Beyond 1000” and aims to enhance corporate value by promoting these growth strategies in a steady manner.

- 1) Strategic development of the global market and expansion of affected areas and treatment areas
- 2) Creating new businesses in global niche markets
- 3) Develop R&D and production system optimized for global expansion
- 4) Establish management structure for sustainable growth

As a result of advancing its businesses in line with these strategies, the Group’s performance for the six months ended on December 31, 2024 progressed favorably as follows.

Net sales amounted to 61,491 million yen (an increase of 13.2% year on year), driven mainly by the strong performance of the Medical Division both domestically and internationally, supported by continued market share growth and the exchange rate impact of stronger foreign currencies.

Gross profit totaled 41,549 million yen (an increase of 18.1% year on year), due to the increase in net sales and improvement in the gross profit margin.

Operating profit was 17,395 million yen (an increase of 28.9% year on year), despite an increase in selling, general and administrative expenses, such as an increase in sales-related expenses aimed at strengthening sales in the non-cardiovascular field in the U.S. and in new fields in Japan, as well as an increase in R&D expenses.

Ordinary profit was 16,821 million yen (an increase of 24.9% year on year), despite an increase in foreign exchange losses.

Profit attributable to owners of parent was 12,261 million yen (an increase of 24.9% year on year), mainly due to non-occurrence of loss on valuation of investment securities and the recording of a reversal of allowance for doubtful accounts as extraordinary income.

Foreign exchange rates used for the six months ended December 31, 2024:

151.00 yen per U.S. dollar (146.35 yen for the same period of the previous fiscal year, up 3.2%)

163.37 yen per euro (158.20 yen for the same period of the previous fiscal year, up 3.3%)

21.00 yen per Chinese yuan (20.20 yen for the same period of the previous fiscal year, up 4.0%)

4.39 yen per Thai baht (4.14 yen for the same period of the previous fiscal year, up 6.0%)

The operating results for each segment are outlined below.

From the beginning of the six months ended December 31, 2024, the method for measuring profit or loss in reportable segments has been changed. For details, please refer to “2. Semi-annual consolidated financial statements and major notes (4) Notes to semi-annual consolidated financial statements (Segment information, etc.) II. Six months ended December 31, 2024 2. Disclosure of changes, etc. in reportable segments.”

For comparative segment information, the figures for the six months ended December 31, 2023 have been restated to reflect the new measurement method for segment information.

#### <Medical Division>

In the Medical Division, net sales remained brisk, increasing mainly due to continued market share growth across all regions and the exchange rate impact of stronger foreign currencies.

In the domestic market, net sales increased thanks to steady performance in the cardiovascular field, along with strong market recognition of neurovascular products and peripheral vascular products (imported purchased products) in the non-cardiovascular field.

In the overseas market, net sales increased in both the cardiovascular and non-cardiovascular fields. In the cardiovascular field, despite temporary transactions in the Europe region, where Eastern European distributors placed concentrated full-year orders in the three months ended September 30, 2023, net sales progressed very favorably across all regions, primarily for PCI guide wires and penetration catheters. In the non-cardiovascular field, despite a decline in OEM transactions in the U.S., net sales increased mainly due to the strong performance of neurovascular products in the Chinese market and abdominal vascular products in the U.S. market.

As a result, net sales totaled 55,763 million yen (an increase of 15.3% year on year).

Segment profit amounted to 18,518 million yen (an increase of 32.0% year on year).

<Device Division>

In the Device Division, net sales decreased due to a decline in both medical components and industrial components.

As for medical components, net sales decreased mainly due to decreasing transactions in robotics-related components in the domestic market and in cardiovascular inspection catheter components for the U.S. companies in the overseas market.

As for industrial components, net sales decreased mainly due to a decrease in leisure-related transactions in the overseas market, despite increases in construction-related transactions in the domestic market and OA equipment-related transactions in the overseas market.

As a result, net sales totaled 5,727 million yen (a decrease of 4.1% year on year).

Segment profit amounted to 2,457 million yen (a decrease of 14.5% year on year), due to a decrease in revenues from external customers.

(2) Explanation of financial position

As of December 31, 2024, total assets amounted to 190,130 million yen, a decrease of 1,484 million yen from the end of the previous fiscal year.

This was mainly due to decreases of 1,115 million yen in notes and accounts receivable - trade, 743 million yen in merchandise and finished goods, and 964 million yen in work in process, despite an increase of 1,906 million yen in cash and deposits.

As for liabilities, total liabilities amounted to 31,207 million yen, a decrease of 8,445 million yen from the end of the previous fiscal year. This was mainly due to decreases of 4,033 million yen in short-term borrowings and 6,074 million yen in other in current liabilities, despite an increase of 903 million yen in long-term borrowings.

As for net assets, total net assets amounted to 158,923 million yen, an increase of 6,961 million yen from the end of the previous fiscal year. This was mainly due to an increase of 6,728 million yen in retained earnings.

(3) Explanation of forecasts including consolidated results forecast

In the six months ended December 31, 2024, performance progressed favorably, with both net sales and profit exceeding initial forecasts.

At present, the Company is reviewing and assessing several factors for the second half of the fiscal year. These include the sales outlook, particularly in China and Asia, where the number of cases and our market share remain strong. However, in 2025, the Company discovered violative inflows of our products from the Asian region into China, and is currently evaluating the impact of this issue. Additionally, the Company is scrutinizing the outlook for the gross profit margin, which remains strong but requires further assessment, considering the effects of process transfers. The Company is also examining additional costs, such as bonuses and salary increases, as part of our review and decision-making process. Given the many uncertainties involved, the Company has decided to maintain the results forecast announced on August 14, 2024. If determining that the likelihood of changes has increased significantly, the Company will take appropriate action accordingly.

## 2. Semi-annual consolidated financial statements and major notes

### (1) Semi-annual consolidated balance sheet

(Million yen)

|   | Previous consolidated fiscal year<br>(June 30, 2024) | Six months under review<br>(December 31, 2024) |
|---|--|--|
| <b>Assets</b>                                       |  |  |
| Current assets                                      |  |  |
| Cash and deposits                                   | 35,658   | 37,564   |
| Notes and accounts receivable - trade               | 17,676   | 16,561   |
| Electronically recorded monetary claims - operating | 1,913  | 2,018  |
| Securities  | 3,000  | 3,999  |
| Merchandise and finished goods                      | 9,282  | 8,539  |
| Work in process                                     | 12,298   | 11,333   |
| Raw materials and supplies                          | 7,763  | 7,141  |
| Other   | 7,609  | 6,240  |
| Allowance for doubtful accounts                     | -505   | -406   |
| Total current assets                                | 94,696   | 92,994   |
| Non-current assets                                  |  |  |
| Property, plant and equipment                       |  |  |
| Buildings and structures, net                       | 31,585   | 31,452   |
| Other, net  | 28,543   | 29,049   |
| Total property, plant and equipment                 | 60,129   | 60,501   |
| Intangible assets                                   |  |  |
| Goodwill  | 6,910  | 6,218  |
| Other   | 10,048   | 9,178  |
| Total intangible assets                             | 16,959   | 15,397   |
| Investments and other assets                        | 19,828   | 21,237   |
| Total non-current assets                            | 96,917   | 97,135   |
| Total assets  | 191,614  | 190,130  |

(Million yen)

|  | Previous consolidated fiscal year<br>(June 30, 2024) | Six months under review<br>(December 31, 2024) |
|--|--|--|
| <b>Liabilities</b>   |  |  |
| Current liabilities  |  |  |
| Notes and accounts payable - trade                                   | 2,289  | 2,383  |
| Electronically recorded obligations - operating                      | 625  | 588  |
| Short-term borrowings  | 5,615  | 1,581  |
| Income taxes payable   | 2,683  | 4,142  |
| Provision for bonuses  | 2,700  | 1,598  |
| Other  | 15,580   | 9,506  |
| Total current liabilities  | 29,494   | 19,801   |
| Non-current liabilities  |  |  |
| Long-term borrowings   | 1,087  | 1,991  |
| Provision for retirement benefits for directors (and other officers) | 19   | 19   |
| Retirement benefit liability   | 2,851  | 3,039  |
| Other  | 6,199  | 6,355  |
| Total non-current liabilities  | 10,157   | 11,405   |
| Total liabilities  | 39,652   | 31,207   |
| <b>Net assets</b>  |  |  |
| Shareholders' equity   |  |  |
| Share capital  | 18,860   | 18,860   |
| Capital surplus  | 21,779   | 21,779   |
| Retained earnings  | 90,742   | 97,471   |
| Treasury shares  | -7   | -7   |
| Total shareholders' equity   | 131,375  | 138,104  |
| Accumulated other comprehensive income                               |  |  |
| Valuation difference on available-for-sale securities                | 2,689  | 2,262  |
| Foreign currency translation adjustment                              | 17,142   | 17,783   |
| Remeasurements of defined benefit plans                              | 9  | 2  |
| Total accumulated other comprehensive income                         | 19,841   | 20,048   |
| Non-controlling interests  | 744  | 769  |
| Total net assets   | 151,961  | 158,923  |
| <b>Total liabilities and net assets</b>                              | <b>191,614</b>                                       | <b>190,130</b>                                 |



## (2) Semi-annual consolidated statements of income and comprehensive income

## Semi-annual consolidated statement of income

(Million yen)

|  | Previous six months period<br>(from July 1, 2023 to<br>December 31, 2023) | Six months under review<br>(from July 1, 2024 to<br>December 31, 2024) |
|--|---|--|
| Net sales  | 54,341  | 61,491   |
| Cost of sales                                    | 19,150  | 19,941   |
| Gross profit                                     | 35,191  | 41,549   |
| Selling, general and administrative expenses     | 21,693  | 24,154   |
| Operating profit                                 | 13,498  | 17,395   |
| Non-operating income                             |   |  |
| Interest income                                  | 58  | 48   |
| Dividend income                                  | 35  | 81   |
| Subsidy income                                   | 42  | 155  |
| Other  | 164   | 157  |
| Total non-operating income                       | 301   | 442  |
| Non-operating expenses                           |   |  |
| Interest expenses                                | 152   | 181  |
| Foreign exchange losses                          | 106   | 784  |
| Other  | 69  | 51   |
| Total non-operating expenses                     | 328   | 1,016  |
| Ordinary profit                                  | 13,471  | 16,821   |
| Extraordinary income                             |   |  |
| Gain on sale of investment securities            | –   | 23   |
| Reversal of allowance for doubtful accounts      | –   | 100  |
| Total extraordinary income                       | –   | 123  |
| Extraordinary losses                             |   |  |
| Loss on valuation of investment securities       | 99  | –  |
| Other  | 0   | –  |
| Total extraordinary losses                       | 99  | –  |
| Profit before income taxes                       | 13,371  | 16,945   |
| Income taxes - current                           | 3,138   | 5,008  |
| Income taxes - deferred                          | 355   | -355   |
| Total income taxes                               | 3,494   | 4,652  |
| Profit   | 9,876   | 12,293   |
| Profit attributable to non-controlling interests | 56  | 31   |
| Profit attributable to owners of parent          | 9,820   | 12,261   |

## Semi-annual consolidated statement of comprehensive income

(Million yen)

|  | Previous six months period<br>(from July 1, 2023 to<br>December 31, 2023) | Six months under review<br>(from July 1, 2024 to<br>December 31, 2024) |
|--|---|--|
| Profit   | 9,876   | 12,293   |
| Other comprehensive income                                     |   |  |
| Valuation difference on available-for-sale securities          | -94   | -426   |
| Foreign currency translation adjustment                        | -73   | 640  |
| Remeasurements of defined benefit plans, net of tax            | -8  | -6   |
| Total other comprehensive income                               | -176  | 207  |
| Comprehensive income   | 9,700   | 12,501   |
| Comprehensive income attributable to                           |   |  |
| Comprehensive income attributable to owners of parent          | 9,643   | 12,475   |
| Comprehensive income attributable to non-controlling interests | 56  | 25   |

## (3) Semi-annual consolidated statement of cash flows

(Million yen)

|   | Previous six month period<br>(from July 1, 2023 to<br>December 31, 2023) | Six months under review<br>(from July 1, 2024 to<br>December 31, 2024) |
|---|--|--|
| Cash flows from operating activities                          |  |  |
| Profit before income taxes                                    | 13,371   | 16,945   |
| Depreciation  | 4,154  | 4,693  |
| Increase (decrease) in provision for bonuses                  | -283   | -1,084   |
| Interest expenses   | 152  | 181  |
| Amortization of goodwill                                      | 605  | 622  |
| Decrease (increase) in trade receivables                      | -3,204   | 772  |
| Decrease (increase) in inventories                            | 1,492  | 2,599  |
| Increase (decrease) in trade payables                         | -528   | 41   |
| Decrease (increase) in consumption taxes<br>refund receivable | 844  | 1,327  |
| Increase (decrease) in accounts payable - other               | -502   | -688   |
| Decrease (increase) in accounts receivable -<br>other         | 52   | 148  |
| Increase (decrease) in advances received                      | -1,069   | -4,293   |
| Other, net  | 634  | 272  |
| Subtotal  | 15,718   | 21,537   |
| Interest and dividends received                               | 87   | 145  |
| Interest paid   | -61  | -210   |
| Income taxes paid   | -3,127   | -3,188   |
| Net cash provided by (used in) operating<br>activities        | 12,617   | 18,284   |

(Million yen)

|  | Previous six month period<br>(from July 1, 2023 to<br>December 31, 2023) | Six months under review<br>(from July 1, 2024 to<br>December 31, 2024) |
|--|--|--|
| Cash flows from investing activities   |  |  |
| Proceeds from redemption of securities   | 2,000  | –  |
| Purchase of property, plant and equipment  | -4,275   | -4,035   |
| Purchase of intangible assets  | -141   | -214   |
| Purchase of investment securities  | -159   | -3,074   |
| Other, net   | -452   | 311  |
| Net cash provided by (used in) investing activities                                  | -3,029   | -7,013   |
| Cash flows from financing activities   |  |  |
| Net increase (decrease) in short-term borrowings                                     | -6,307   | -507   |
| Proceeds from long-term borrowings   | –  | 2,000  |
| Repayments of long-term borrowings   | -120   | -4,622   |
| Dividends paid   | -3,933   | -5,533   |
| Purchase of shares of subsidiaries not resulting in change in scope of consolidation | -1,346   | –  |
| Repayments of lease liabilities  | -142   | -206   |
| Other, net   | -0   | -0   |
| Net cash provided by (used in) financing activities                                  | -11,850  | -8,869   |
| Effect of exchange rate change on cash and cash equivalents                          | -114   | -495   |
| Net increase (decrease) in cash and cash equivalents                                 | -2,376   | 1,906  |
| Cash and cash equivalents at beginning of period                                     | 34,884   | 35,658   |
| Cash and cash equivalents at end of period   | 32,508   | 37,564   |

(4) Notes to semi-annual consolidated financial statements

(Note on entity's ability to continue as going concern)

Not applicable.

(Notes in the case of significant changes in amount of shareholders' equity)

Not applicable.

(Changes in accounting policies)

(Application of accounting standard for current income taxes, etc.)

The Company has applied the "Accounting Standard for Current Income Taxes" (ASBJ Statement No. 27, October 28, 2022; the "2022 Revised Accounting Standard"), etc. from the beginning of the six months ended December 31, 2024.

For the revisions to the accounting classification of current income taxes (taxation on other comprehensive income), the Company follows the transitional treatment specified in the proviso to Paragraph 20-3 of the 2022 Revised Accounting Standard and the transitional treatment specified in the proviso to Paragraph 65-2 (2) of the "Guidance on Accounting Standard for Tax Effect Accounting" (ASBJ Guidance No. 28, October 28, 2022; the "2022 Revised Guidance").

For the revisions related to the review of treatment in consolidated financial statements when conducting a tax deferral of gains or losses on sales arising from the sale of subsidiary shares, etc. between consolidated companies, the Company has applied the 2022 Revised Guidance from the beginning of the six months ended December 31, 2024.

This application has no impact on the consolidated financial statements for the six months ended on December 31, 2024.

(Segment Information, etc.)

[Segment Information]

I Six months ended December 31, 2023 (from July 1, 2023 to December 31, 2023)

Disclosure of sales and profit (loss) for each reportable segment

(Million yen)

|                                  | Reportable segment |                 |        | Adjustments<br>(Note 1) | Per semi-annual<br>consolidated<br>financial<br>statements<br>(Note 2) |
|----------------------------------|--------------------|-----------------|--------|-------------------------|--|
|                                  | Medical Division   | Device Division | Total  |                         |  |
| Net sales                        |                    |                 |        |                         |  |
| Revenues from external customers | 48,369             | 5,972           | 54,341 | —                       | 54,341   |
| Transactions with other segments | —                  | 6,761           | 6,761  | -6,761                  | —  |
| Total                            | 48,369             | 12,733          | 61,103 | -6,761                  | 54,341   |
| Segment profit                   | 14,026             | 2,875           | 16,901 | -3,403                  | 13,498   |

- Notes:
1. The adjustment to segment profit includes corporate expenses that are not allocated to each reportable segment. Corporate expenses mainly consist of general and administrative expenses that do not belong to any reportable segment.
  2. Segment profit is adjusted with the operating profit in the semi-annual consolidated statement of income.

II Six months ended December 31, 2024 (from July 1, 2024 to December 31, 2024)

1. Disclosure of sales and profit (loss) for each reportable segment

(Million yen)

|                                  | Reportable segment |                 |        | Adjustments<br>(Note 1) | Per semi-annual<br>consolidated<br>financial<br>statements<br>(Note 2) |
|----------------------------------|--------------------|-----------------|--------|-------------------------|--|
|                                  | Medical Division   | Device Division | Total  |                         |  |
| Net sales                        |                    |                 |        |                         |  |
| Revenues from external customers | 55,763             | 5,727           | 61,491 | —                       | 61,491   |
| Transactions with other segments | —                  | 7,288           | 7,288  | -7,288                  | —  |
| Total                            | 55,763             | 13,016          | 68,780 | -7,288                  | 61,491   |
| Segment profit                   | 18,518             | 2,457           | 20,976 | -3,581                  | 17,395   |

- Notes:
1. The adjustment to segment profit includes corporate expenses that are not allocated to each reportable segment. Corporate expenses mainly consist of general and administrative expenses that do not belong to any reportable segment.
  2. Segment profit is adjusted with the operating profit in the semi-annual consolidated statement of income.

2. Disclosure of changes, etc. in reportable segments

(Change in measurement method of profit (loss) for reportable segments)

From the beginning of the six months ended December 31, 2024, general and administrative expenses for certain consolidated subsidiaries, which were previously included in the Medical Division and Device Division segments, have been reclassified as general and administrative expenses that do not belong to any reportable segment (corporate expenses) due to organizational expansion.

Segment information for the six months ended December 31, 2023 has been prepared and disclosed based on the revised measurement method.

(Revenue recognition)

Disaggregation of revenue from contracts with customers

(1) Breakdown by type

Six months ended December 31, 2023 (from July 1, 2023 to December 31, 2023)

(Million yen)

|                       | Reportable segment |                 |        |
|-----------------------|--------------------|-----------------|--------|
|                       | Medical Division   | Device Division | Total  |
| Cardiovascular        | 36,300             | —               | 36,300 |
| Non-cardiovascular    | 7,635              | —               | 7,635  |
| OEM                   | 4,434              | —               | 4,434  |
| Medical Components    | —                  | 3,857           | 3,857  |
| Industrial Components | —                  | 2,114           | 2,114  |
| Total                 | 48,369             | 5,972           | 54,341 |

Six months ended December 31, 2024 (from July 1, 2024 to December 31, 2024)

(Million yen)

|                       | Reportable segment |                 |        |
|-----------------------|--------------------|-----------------|--------|
|                       | Medical Division   | Device Division | Total  |
| Cardiovascular        | 42,390             | —               | 42,390 |
| Non-cardiovascular    | 9,506              | —               | 9,506  |
| OEM                   | 3,866              | —               | 3,866  |
| Medical Components    | —                  | 3,787           | 3,787  |
| Industrial Components | —                  | 1,940           | 1,940  |
| Total                 | 55,763             | 5,727           | 61,491 |

(2) Breakdown by region

Six months ended December 31, 2023 (from July 1, 2023 to December 31, 2023)

(Million yen)

|               | Reportable segment |                 |        |
|---------------|--------------------|-----------------|--------|
|               | Medical Division   | Device Division | Total  |
| Japan         | 7,247              | 1,430           | 8,678  |
| North America | 10,604             | 2,208           | 12,813 |
| Europe        | 11,243             | 188             | 11,431 |
| China         | 12,182             | 298             | 12,481 |
| Others        | 7,091              | 1,845           | 8,937  |
| Total         | 48,369             | 5,972           | 54,341 |

Six months ended December 31, 2024 (from July 1, 2024 to December 31, 2024)

(Million yen)

|               | Reportable segment |                 |        |
|---------------|--------------------|-----------------|--------|
|               | Medical Division   | Device Division | Total  |
| Japan         | 7,866              | 1,396           | 9,262  |
| North America | 11,130             | 1,786           | 12,916 |
| Europe        | 11,555             | 232             | 11,788 |
| China         | 16,546             | 257             | 16,804 |
| Others        | 8,664              | 2,054           | 10,718 |
| Total         | 55,763             | 5,727           | 61,491 |

(Significant subsequent events)

Not applicable.